Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer’s Patients: A Prospective Comparative Study

Close metadata

OBJECTIVE

To evaluate the long-term effects of annual course therapy with Cerebrolysin on cognitive functioning and the risk of transition to dementia in relatives of patients with Alzheimer’s disease (AD) with amnestic-type mild cognitive decline syndrome (aMCI) in comparison with the same group untreated relatives.

MATERIAL AND METHODS

The cohort included 88 first-degree relatives of BA patients with aMCI syndrome aged 50 to 82 years (mean age 65.0±9.9 years) of which 46 people received course therapy with Cerebrolysin and 42 people were not treated. Clinical, neuropsychological, statistical methods were used. Conducted annual course therapy with Cerebrolysin (a total of 3 courses of infusion therapy: for a course of 20 intravenous infusions of 20 ml of Cerebrolysin in 100 ml of isotonic saline) followed by a follow-up study after 3 months after the end of the therapeutic period. The dynamics of cognitive functioning in the therapeutic group was compared with the corresponding dynamics in the comparison group over the same period. The assessment was carried out on day 0, by the end of 1, 14, 27 and 30 months research.

RESULTS

In the therapeutic group, according to the CGI-I scale, by the end of the 3rd course of therapy, in 95.7% of cases, a pronounced or moderate improvement was achieved after each of the courses on all scales and tests. In this group, by the end of the therapeutic period, a significant improvement in the initial mean group scores was established. According to the all scales and tests, a significant improvement of the initial average group scores was found after each course of therapy (p<0.05). In the comparison group there was a significant deterioration (p<0.05) of the average group scores of most of the cognitive scales and test by the end of the observation. The annual conversion from aMCI to dementia due to probable AD was 9.5% only in the comparison group. The average group indicators of all scales and tests significantly worsened starting from the 14th month of observation in the comparison group.

CONCLUSION

The absence of cases of aMCI conversion to dementia in the treated patients for 2.5 years of observation can serve as confirmation of a disease-modifying effect in Cerebrolysin. These results indicate the need for more extensive clinical studies of the preventive effects of Cerebrolysin and to explore the possibility of including such therapy in drug prevention programs for AD in people at high risk for this disease.

Keywords:

Alzheimer’s disease

mild cognitive impairment

the first-degree relatives of patients with Alzheimer’s disease

therapy

Cerebrolysin

Authors:

Selezneva N.D.

Mental Health Research Center

SPIN RSCI: 7488-1790
Scopus AuthorID: 57195633330
ResearcherID: C-7026-2016
ORCID: 0000-0001-6999-3280

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Received:

21.06.2023

Accepted:

10.08.2023

List of references:

Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the diagnosis of dementia. London, England: Alzheimer’s Disease International. 2021.
Korovaitseva GI, Shcherbatykh TV, Selezneva ND, et al. Geneticheskaya assotsiatsiya mezhdu allelyami gena apolipoproteina E (AROE) i razlichnymi formami bolezni Al’tsgeimera. Genetika. 2001;37(4):529-533. (In Russ.).
Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108:459-473. https://doi.org/10.1007/s007020170067
Liu W, Leng H, Zhu Z, Chen G. Analysis of the content of ten kinds of metal elements in cerebrolysin by atomic absorption spectrophotometry. Guang Pu Xue Yu Guang Pu Fen Xi. 2001;21:397-399.
Gromova OA, Kudrin AV, Kataev SI, Mazina SS, Volkov AYu. Effects of cerebrolysin on trace element homeostasis in the brain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2003;103:59-61. (In Russ.).
Zhang L, Chopp M, Meier DH, et al. Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. Stroke. 2013;44:1965-1972. https://doi.org/10.1161/strokeaha.111.000831
Zhang Y, Chopp M, Meng Y, et al. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. Journal of Neurosugery. 2013;118:1343-1355. https://doi.org/10.3171/2013.3.jns122061
Wenzel J, Stender G, Duwe G. Development of neuron structure of the fascia dentata in the rat. Neurohistologicomorphometric, ultrastructural and experimental study. J Hirnforsch. 1981;22:629-683.
Windisch M, Piswanger A. The effect and changes in oxygen consumption of rat brain homogenates: in vitro effect of a peptide derivative. Arzneimittelforschung. 1985;35:1225-1227.
Gschanes A, Windisch M. Early postnatal treatment with peptide preparations influences spatial navigation of young and adult rats. Behav Brain Res. 1999;100:161-166.
Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry. 1994;27:32-40.
Grundman M, Corey-Bloom J, Thal LJ. Perspectives in clinical Alzheimer’s disease research and the development of Cerebrolysin Review — Wise Young — Page 19 antidementia drugs. J Neural Transm Suppl. 1998;53:255-275.
Bae CY, Cho CY, Cho K, et al. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc. 2000;48:1566-1571.
Ruther E, Ritter R, Apecechea M, et al. Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm. 2000;107:815-829.
Windisch M. Approach towards an integrative drug treatment of Alzheimer’s disease. J Neural Transm Suppl. 2000;59:301-313.
Ruether E, Husmann R, Kinzler E, et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol. 2001;16:253-263.
Gavrilova SI, Kolykhalov IV, Korovaitseva GI, et al. ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;105:27-34. (In Russ.).
Roshchina IF, Kolykhalov IV, Selezneva ND. et al. The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine in Alzheimer’s disease patients (neuropsychological investigation). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999;99:43-46. (In Russ.).
Selezneva ND, Gavrilova SI, Kolykhalov IV. Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first-degree relatives of patients with Alzheimer’s disease: the role of the ApoE genotype. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(10-2):31-38. (In Russ.). https://doi.org/10.17116/jnevro202012010231
Selezneva ND, Roshchina IF, Korovaytseva GI, Gavrilova SI. Prevention of progression of cognitive deficiency in relatives (1st degree of kinship) of patients with Alzheimer’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;10:30-36. (In Russ.). https://doi.org/10.17116/jnevro201811810130
Gavrilova SI, Fedorova YaB, Kolyhalov IV, et al. The therapeutic potential of cerebrolysin in the preventive treatment of Alzheimer’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2008;108(8):24-29. (In Russ.).
Gavrilova SI, Kolyhalov IV, Fyodorova YaB, et al. Possibilities of preventive therapy for Alzheimer’s disease: the results of a 3-year prospective open comparative study of the efficacy and safety of course therapy with cerebrolysin and cavinton in elderly patients with mild cognitive decline syndrome. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2010;110(1):62-69. (In Russ.).
Selezneva ND, Gavrilova SI, Roshchina IF, Ponomareva YeV. Tsitikolin v lechenii kognitivnoy nedostatochnosti u rodstvennikov 1-y stepeni rodstva patsiyentov s bolezn’yu Al’tsgeymera: vliyaniye ApoE genotipa. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2021;121(10 vyp. 2):30-36. (In Russ.). https://doi.org/10.17116/jnevro202112110230
Selezneva ND, Roshchina IF, Gavrilova SI. The Effectiveness of Course Therapy with Actovegin of Minimal Cognitive Dysfunction in 1st-Degree Relatives of Patients with Alzheimer’s Disease: the Role of ApoE Genotype. Psychiatry. 2023;21(1):52-61. (In Russ.). https://doi.org/10.30629/2618-6667-2023-21-1-52-61
Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308. https://doi.org/10.1001/archneur.56.3.303
Folstein MF, Folstein SE, Mchugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975;12:189-198.
Morris JC. The Clinical Dementia Rating (CDR): Current vision and scoring rules. Neurology. 1993;43:2412-2414.
Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia Am J Psychiatry. 1982;139(9):1136-1139.
Padhi A, Fineberg N. Clinical Global Impression Scales. In: Stolerman I.P. (eds). Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. 2010. https://doi.org/10.1007/978-3-540-68706-1_1422
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005, Apr;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x.
Neuropsychological diagnostics. Classical stimulus materials. Aut.-stat. Balashova EYu, Kovyazina MS. Ed. Genesis. 2022. (In Russ.).
Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test (2nd ed.). Lea & Febiger. Philadelphia. 1983. 120 p.
Wechsler D. Manual for the Wechsler Adult Intelligence Scale. N.Y., 1955;230 p.
Shulman KI, Shedletsky R., Silver IL. The challenge of time: clock-drawing and cognitive function in the elderly. International Journal of Geriatric Psychiatry. 1986;1:135-140.
Rubinstein SYa. Experimental methods of pathopsychology and experience of their application in the clinic. practical guide. Stimulus material (set of 2 books). Ed. Psychotherapy, 2010, 224 s. (In Russ.).
Benton AL. A Visual Retention Test for Clinical Use. Archives of Neurology and Psychiatry. 1945;4(3):212-216. https://doi.org/10.1001/archneurpsyc.1945.02300090051008
Belaus A Fernández LA, Farías-Sarquis Ya, Adrián M, Bueno M. Mattis Dementia Rating Scale. Rev. Chil. Neuropsicol. 2015;10(1):8-13.
Raygorodskiy DYa. Prakticheskaya psikhodiagnostika. Metodiki i testy. Izdatel’stvo Bakhrakh-M, 2011. (In Russ.).
Lingjaerde O, Ahlfors U, Bch P, Dencker S, Elgen K. The UKU Side Effect Rating Scale. Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic-Treated Patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. https://doi.org/10.1111/j.1600-0447.1987.tb10566.x
Rebrova OYu. Statisticheskiy analyz meditsinskikh dannykh. Primeneniye paketa prikladnykh programm Statistica. M: «MediaSfera». 2000, 312 s. (In Russ.).
Medvecky J, Jassova Z, Medvecka E. Findings in treatment with cerebrolysin. Cesk Psychiatr. 1982;78:308-311.
Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Medicinal Research Reviews. 2021;41(5):2775-2803. https://doi.org/10.1002/med.21722

Close metadata